Two major studies from a significant clinical trial involving over 17,000 adults report that semaglutide effectively reduces weight and waist circumference across diverse demographics over four years. The medication not only offers sustained weight loss but also presents cardiovascular benefits irrespective of the initial weight or the extent of weight reduction. These studies, presented at the European Congress on Obesity, underline the potential for semaglutide to impact public health significantly by managing obesity-related conditions.
Two important studies stemming from the largest and most prolonged clinical trial of semaglutide’s impact on weight in more than 17,000 non-diabetic adults with overweight and obesity reveal that participants lost an average of 10% of their body weight and more than 7 centimeters from their waistline over four years. Clinically meaningful weight loss was achieved by men and women of all races, ages, and body sizes, across all regions, with a lower rate of serious adverse events compared with placebo. Over half of adults taking semaglutide moved down at least one BMI category after 2 years compared to 16% receiving placebo, and 12% reached a healthy BMI (25 kg/m2 or less) compared with 1% in the placebo group.
Importantly, the findings also indicate that semaglutide delivers cardiovascular benefits irrespective of starting weight and the amount of weight lost—suggesting that even patients with mild obesity or those not losing weight are .